There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk
There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk
Statins are one of the most widely used drug classes, with approximately 50 million prescriptions dispensed in England alone in 2008. Their efficacy and safety in significantly reducing cardiovascular events in moderate-to-high-risk patients has been well documented, both in primary and secondary prevention. 1 Commonly reported side-effects include muscle aches and increases in liver enzymes, but, in general, statins are well tolerated with a low incidence of side-effects. However, the recent collaborative meta-analysis of 13 major placebo-controlled statin trials by Sattar and colleagues reports a 9% increased risk for incident diabetes over 4 years (OR 1.09; 95% CI 1.02-1-17) in patients randomised to statins compared to those assigned to placebo. Heterogeneity between trials was low (I 2=11%), suggesting that this risk appears to be a true class effect, despite known differences in lipophilicity and metabolic clearance pathways between individual statin drugs
84-85
Bhatia, Lokpal
4cb41d34-0a6b-47fe-94c9-b40e1fbc3e09
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
June 2010
Bhatia, Lokpal
4cb41d34-0a6b-47fe-94c9-b40e1fbc3e09
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Bhatia, Lokpal and Byrne, Christopher D.
(2010)
There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk.
Evidence-Based Medicine, 15 (3), .
(doi:10.1136/ebm1075).
(PMID:20522688)
Abstract
Statins are one of the most widely used drug classes, with approximately 50 million prescriptions dispensed in England alone in 2008. Their efficacy and safety in significantly reducing cardiovascular events in moderate-to-high-risk patients has been well documented, both in primary and secondary prevention. 1 Commonly reported side-effects include muscle aches and increases in liver enzymes, but, in general, statins are well tolerated with a low incidence of side-effects. However, the recent collaborative meta-analysis of 13 major placebo-controlled statin trials by Sattar and colleagues reports a 9% increased risk for incident diabetes over 4 years (OR 1.09; 95% CI 1.02-1-17) in patients randomised to statins compared to those assigned to placebo. Heterogeneity between trials was low (I 2=11%), suggesting that this risk appears to be a true class effect, despite known differences in lipophilicity and metabolic clearance pathways between individual statin drugs
Text
84.full.pdf
- Version of Record
More information
Published date: June 2010
Identifiers
Local EPrints ID: 176479
URI: http://eprints.soton.ac.uk/id/eprint/176479
ISSN: 1356-5524
PURE UUID: 987d67fb-f4b0-4319-940c-cbbc23a2919b
Catalogue record
Date deposited: 08 Mar 2011 09:47
Last modified: 14 Mar 2024 02:43
Export record
Altmetrics
Contributors
Author:
Lokpal Bhatia
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics